TD Asset Management Inc. Makes New $617,000 Investment in Trillium Therapeutics Inc (NASDAQ:TRIL)

Share on StockTwits

TD Asset Management Inc. bought a new position in shares of Trillium Therapeutics Inc (NASDAQ:TRIL) (TSE:TR) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 76,575 shares of the biotechnology company’s stock, valued at approximately $617,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Deutsche Bank AG bought a new stake in shares of Trillium Therapeutics during the first quarter valued at approximately $10,022,000. Rockefeller Capital Management L.P. bought a new stake in shares of Trillium Therapeutics during the second quarter valued at approximately $40,000. Barclays PLC raised its position in shares of Trillium Therapeutics by 269.2% during the second quarter. Barclays PLC now owns 484,239 shares of the biotechnology company’s stock valued at $3,917,000 after buying an additional 353,069 shares during the last quarter. Aigen Investment Management LP bought a new stake in shares of Trillium Therapeutics during the second quarter valued at approximately $167,000. Finally, Vident Investment Advisory LLC bought a new stake in shares of Trillium Therapeutics during the second quarter valued at approximately $1,433,000. Institutional investors own 66.60% of the company’s stock.

NASDAQ TRIL opened at $14.67 on Wednesday. The company has a fifty day moving average of $9.57 and a two-hundred day moving average of $6.93. The firm has a market capitalization of $1.24 billion, a price-to-earnings ratio of -5.96 and a beta of 2.23. Trillium Therapeutics Inc has a 52 week low of $0.24 and a 52 week high of $15.36.

Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) last posted its quarterly earnings data on Wednesday, August 12th. The biotechnology company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.18). The business had revenue of $0.12 million for the quarter. As a group, research analysts anticipate that Trillium Therapeutics Inc will post -1.02 EPS for the current fiscal year.

Several equities research analysts recently weighed in on the stock. HC Wainwright upgraded shares of Trillium Therapeutics from a “neutral” rating to a “buy” rating and set a $16.50 price target on the stock in a research report on Thursday, September 10th. Zacks Investment Research upgraded shares of Trillium Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 18th. JMP Securities boosted their price target on shares of Trillium Therapeutics from $10.00 to $14.00 and gave the stock a “market outperform” rating in a research report on Wednesday, September 9th. They noted that the move was a valuation call. Craig Hallum assumed coverage on shares of Trillium Therapeutics in a research report on Monday, August 17th. They issued a “buy” rating and a $15.00 price target on the stock. Finally, BidaskClub upgraded shares of Trillium Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 12th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $12.44.

Trillium Therapeutics Company Profile

Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trials for advanced hematologic malignancies, and solid tumors and mycosis fungoides.

See Also: Net Asset Value

Want to see what other hedge funds are holding TRIL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Trillium Therapeutics Inc (NASDAQ:TRIL) (TSE:TR).

Institutional Ownership by Quarter for Trillium Therapeutics (NASDAQ:TRIL)

Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

AQR Capital Management LLC Has $847,000 Stock Holdings in United Natural Foods Inc
AQR Capital Management LLC Has $847,000 Stock Holdings in United Natural Foods Inc
AQR Capital Management LLC Sells 123,807 Shares of United Natural Foods Inc
AQR Capital Management LLC Sells 123,807 Shares of United Natural Foods Inc
Nuveen Asset Management LLC Sells 37,360 Shares of Big Lots, Inc.
Nuveen Asset Management LLC Sells 37,360 Shares of Big Lots, Inc.
AQR Capital Management LLC Invests $973,000 in Hometrust Bancshares Inc
AQR Capital Management LLC Invests $973,000 in Hometrust Bancshares Inc
Nuveen Asset Management LLC Invests $11.66 Million in Ovintiv
Nuveen Asset Management LLC Invests $11.66 Million in Ovintiv
Nuveen Asset Management LLC Trims Stock Position in Zillow Group Inc
Nuveen Asset Management LLC Trims Stock Position in Zillow Group Inc


© 2006-2020 Ticker Report